吉兰-巴雷综合征的免疫治疗  

Immunotherapy for Guillain-Barrésyndrome

作　　者：谷亚伟 楚旭 赵岚[1] 王利军[1] 王洪新 Gu Yawei;Chu Xu;Zhao Lan;Wang Lijun;Wang Hongxin(Department of Neurology,Fourth Central Hospital Affiliated to Nankai University,Tianjin 300140,China;Unit Four,Medical Department,Xushui District People's Hospital of Baoding,Baoding 072500,China)

机构地区：[1]南开大学附属第四中心医院神经内科,天津300140 [2]保定市徐水区人民医院内4科,保定072550

出　　处：《中华神经医学杂志》2022年第2期207-210,共4页Chinese Journal of Neuromedicine

摘　　要：吉兰-巴雷综合征(GBS)临床一线治疗方式主要包括静脉注射免疫球蛋白和血浆置换,但患者预后差异较大,残障率和病死率均较高,免疫治疗成为近年研究热点。笔者现围绕单克隆抗体层面、免疫调节剂层面及细胞因子层面治疗途径的研究进展进行综述,以期为GBS的免疫治疗提供参考。The first line of clinical treatment for Guillain-BarréSyndrome(GBS)is intravenous immunoglobulin(IVIg)and plasma exchange(PE).However,the prognoses of patients vary greatly,with high disability and mortality rates.Immunotherapy has become a research hotspot in recent years.This paper reviews the research progress of GBS immunotherapy in recent years from the prospect of monoclonal antibody,immunomodulator and cytokines,in order to provide basis for treatment of GBS.

关 键 词：吉兰-巴雷综合征 免疫治疗 单克隆抗体 免疫调节剂 细胞因子 

分 类 号：R745.43[医药卫生—神经病学与精神病学]